Therefore, it would be interesting to observe the impact of the efficacy of GLP-1RAs in individuals with genetic mutations in their NOD2, TLR4 and CD14 genes and patients receiving NOD-2 agonists, such as mifamuratide, which is used as an orphan drug or adjuvant therapy in patients with juvenile and adolescent osteosarcoma [112]. The gene discussed is NOD2; the disease is osteosarcoma.